A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus
Journal of Biological Chemistry · 2024-07 · 300 (7) · 107443
DOI: 10.1016/j.jbc.2024.107443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024-07. Verfasst von Jia Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Macrophage Migration-Inhibitory Factors, Intramolecular Oxidoreductases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAMS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Functional variants of the gene for the cytokine macrophage migration inhibitory factor (MIF) are defined by a 4-nucleotide promoter microsatellite (-794 CATT5-8, rs5844572) and confer risk for autoimmune, infectious, and oncologic diseases. We describe herein the discovery of a prototypic, small molecule inhibitor of MIF transcription with selectivity for high microsatellite repeat number and correspondingly high gene expression. Utilizing a high-throughput luminescent proximity screen, we identify 1-carbomethoxy-5-formyl-4,6,8-trihydroxyphenazine (CMFT) to inhibit the functional interaction between the transcription factor ICBP90 (namely, UHRF1) and the MIF -794 CATT5-8 promoter microsatellite. CMFT inhibits MIF mRNA expression in a -794 CATT5-8 length-dependent manner with an IC50 of 470 nM, and preferentially reduces ICBP90-dependent MIF mRNA and protein expression in high-genotypic versus low-genotypic MIF-expressing macrophages. RNA expression analysis also showed CMFT to downregulate MIF-dependent, inflammatory gene expression with little evidence of off-target metabolic toxicity. These findings provide proof-of-concept for advancing the pharmacogenomic development of precision-based MIF inhibitors for diverse autoimmune and inflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Pharmacology, Yale School of Medicine, New Haven, Connecticut, USA.
- Yale Center for Molecular Discovery, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Medicine, Trinity College Dublin, Dublin, Ireland.
- Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: Richard.Bucala@Yale.edu.
Förderung
- NCI NIH HHS
- NIAMS NIH HHS
- NCATS NIH HHS
Zitieren
APA
Li, J., Leng, L., Pantouris, G., Manjula, R., Piecychna, M., Abriola, L., Hu, B., Lolis, E., Armstrong, M. E., Donnelly, S. C., & Bucala, R. (2024). A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus. Journal of Biological Chemistry, 300(7), 107443. https://doi.org/10.1016/j.jbc.2024.107443
Vancouver
Li J, Leng L, Pantouris G, Manjula R, Piecychna M, Abriola L, et al. A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus. Journal of Biological Chemistry. 2024;300(7):107443. doi:10.1016/j.jbc.2024.107443
BibTeX
@article{Li2024,
author = {Li, Jia and Leng, Lin and Pantouris, Georgios and Manjula, Ramu and Piecychna, Marta and Abriola, Laura and Hu, Buqu and Lolis, Elias and Armstrong, Michelle E and Donnelly, Seamas C and Bucala, Richard},
title = {A small-molecule allele-selective transcriptional inhibitor of the MIF immune susceptibility locus},
journal = {Journal of Biological Chemistry},
year = {2024},
volume = {300},
number = {7},
pages = {107443},
doi = {10.1016/j.jbc.2024.107443}
}
EUVIMED